CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)

RetatrutidePositive
AI Analysis

Summary

Analyst upgrades rating on Eli Lilly following reassessment of retatrutide's risk/reward profile. No specific clinical or regulatory catalyst information provided in headline.

Importance:3/10
Sentiment:
0.60
rating_upgradeanalyst_commentaryrisk_reward_assessment
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 12, 2026 4:15 PM

Read Original